PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1110988
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1110988
The Asia-Pacific syndromic multiplex diagnostic market is projected to register a substantial CAGR of 9.6% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2020, and the forecast period is 2022 to 2029.
Asia-Pacific Syndromic Multiplex Diagnostic Market - By Product and Services (Reagents & Consumables, Instruments, Software & Accessories and Services), Infection type (Viral, Bacterial, Parasites and Fungal), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Sepsis, Meningitis and Others), Panels Type (Respiratory Panel, GI-Enteric Panel, SexuallyTransmitted Disease Panel, Blood-Sepsis Panel, Meningitis panel and Others), End User (Clinical Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, Research Institutes and Others), Country (China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippine, Rest of Asia-Pacific) - Industry Trends and Forecast to 2029.
Increase in prevalence of infectious diseases
Increasing awareness towards early diagnosis
BioFire Diagnostics (A Subsidiary of bioMerieux SA)
Seegene Inc.
Luminex Corporation. A DiaSorin Company
F. Hoffmann-La Roche Ltd
BD
Bio-Rad Laboratories, Inc.
Cepheid (A Subsidiary of Danaher)
QIAGEN
Abbott
Hologic, Inc.
Thermo Fisher Scientific Inc.
Siemens Healthcare GmbH
Biocartis
QuantuMDx Group Ltd.
Prominex Inc.
Curetis (A Subsidiary of OpGen, Inc.)
MiRXES Pte Ltd.